PharmaCyte Biotech, Inc. — Form 8-K
Filed November 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
PharmaCyte Biotech (Holder) exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock in Q/C Technologies, Inc. effective November 15, 2026. As majority holder of Q/C's Series H Preferred Stock (3,000,000 shares), PharmaCyte also consented to extend the Series H maturity date by six months from March 2, 2027 to September 2, 2027. PharmaCyte received demand registration rights for resale of the shares.
Why this rating
Major capital deployment: ~4.98M shares received against ~$6.3M PharmaCyte market cap. Increased control through preferred stock leverage and registration rights. Material but not transformational given equity dilution mechanics.
Tradability signal
NO TRADE
No trade: positive news with only -1.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=592). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $4.56 ▲ 1.79% | at our read · unknown $4.48 | +10 min · unknown $4.48 ▲ 0.00% | +30 min · unknown $4.48 ▲ 0.00% | +1 hr · unknown $4.48 ▲ 0.00% | +4 hrs · unknown $4.25 ▼ 5.13% |
The stock had already moved -1.75% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.